Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 10/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | PRKDC | P78527 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | FASN | P49327 | 3/20 | 0.41 |
| ▸ | ABL1 | P00519 | 2/20 | 0.35 |
| ▸ | ABL2 | P42684 | 2/20 | 0.35 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12710144 | 0.87 | PIK3CG (0.49) | PIK3CGCYP2C9PRKDCKCNH2FASN | |
| SCHEMBL10474 | 0.85 | ABL1 (0.49) | PIK3CGCYP2C9PRKDCKCNH2FASN | |
| SCHEMBL10234 | 0.85 | PIK3CG (0.49) | PIK3CGCYP2C9PRKDCFASNABL1 | |
| SCHEMBL10788 | 0.83 | PIK3CG (0.50) | PIK3CGCYP2C9PRKDCKCNH2FASN | |
| SCHEMBL12733331 | 0.83 | PIK3CG (0.41) | PIK3CGCYP2C9PRKDCKCNH2FASN | |
| SCHEMBL10734 | 0.82 | PIK3CG (0.49) | PIK3CGCYP2C9PRKDCKCNH2FASN | |
| SCHEMBL12710092 | 0.82 | PIK3CG (0.49) | PIK3CGCYP2C9PRKDCKCNH2FASN | |
| SCHEMBL12992493 | 0.78 | PIK3CG (0.76) | PIK3CGCYP2C9PRKDCKCNH2 | |
| SCHEMBL12733383 | 0.72 | PIK3CG (0.43) | PIK3CGCYP2C9PRKDCKCNH2FASN | |
| SCHEMBL10237 | 0.71 | PIK3CG (0.41) | PIK3CGCYP2C9PRKDCKCNH2FASN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011041634-A1 | PYRAZOLE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-04-07 | — | — | WO | disclosed |
| US-20110081316-A1 | PYRAZOLE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-04-07 | — | — | US | disclosed |
| US-20110081316-A1 | PYRAZOLE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110081316-A1 | PYRAZOLE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | PIK3CA, PIK3CD, PIK3CG | PIK3CG 3/4885CYP2C9 2078/4885PRKDC 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.